MTOR and precursor B-cell acute lymphoblastic leukemia: Combination treatment with CX-4945 and the direct mTOR inhibitor, rapamycin, shows synergistic therapeutic effects in vitro and in preclinical models of high-risk B-ALL from Hispanic/Latino children.